On the 15 January 2018 a Bill for the Production of Cannabis for Medicinal Use was introduced by the Honourable Chris Cardona, M.P., Minister for the Economy, Investment and Small Businesses, to permit the local industrial production of cannabis products for medical use in the context of a controlled and supervised environment.

The amendments to the Drug Dependence Act were enacted on 23rd March by Maltese parliament after its third and final reading.

The new law will permit doctors to prescribe cannabis to patients suffering from chronic pain, spasticity in multiple sclerosis and side effects of chemotherapy.

It outlines patients will only be permitted to use non-smoking forms of cannabis-derived products once they obtain a card showing they’ve been approved by Malta’s the Superintendent of Public Health.

License and Letter of Intent

The issuing of a licence is subject to the submission, by the applicant, of documentation, including that for due diligence, required by the Medicines Authority to ensure fulfillment of licencing requirements as well as the compliance with, and attainment of, any other conditions, licences and authorization required under the relevant legislation. Moreover, a letter of intent will be required from Malta Enterprise.

The government also announced that The Malta Enterprise, the country’s economic development agency, has approved five new projects relating to the production of medical cannabis with a capital investment of €30 million (the equivalent of just under C$48 million). Of the five projects, three are Canadian.

Related Post